In spite of consistent progress at the level of basic research and of clinical treatment, acute
myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric …

An essential protein regulatory system in cells is the ubiquitin-proteasome pathway. The
substrate is modified by the ubiquitin ligase system (E1-E2-E3) in this pathway, which is a …

Venetoclax+ hypomethylating agent (Ven‐HMA) is currently the standard frontline therapy
for older/unfit patients with newly diagnosed acute myeloid leukemia (ND‐AML). Our …

The topological indices provide quantitative structural characteristics of drug molecules that
can be utilized to predict or establish correlations with the biological activity …

Although bone marrow mesenchymal stem cells (BM-MSCs)-derived exosomes have been
reported to be closely associated with acute myeloid leukemia (AML) progression and …

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in
newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and …

PI3Kδ is an essential target correlated to the occurrence and development of acute myeloid
leukemia (AML). Herein, we investigated the pyrazolo [3, 4-d] pyrimidine derivatives as …

Core binding factor acute myeloid leukemia (CBF-AML) features the recurrent chromosomal
rearrangements t (8; 21)(q22; 22) and inv (16)(p13. 1q22)/t (16; 16)(p13. 1; q22), which …

Background High expression of immune checkpoints (ICs) and senescence molecules
(SMs) contributes to T cell dysfunction, tumor escape, and progression, but systematic …

With cancer being a leading cause of death globally, there is an urgent need to improve
therapeutic strategies and identify effective chemotherapeutics. This study aims to highlight …